1400651-19-5

Basic information

• Product Name: N-(4-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide
• Synonyms: N-(4-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide
• CAS NO: 1400651-19-5
• Molecular Weight: 306.361
• Mol File: 1400651-19-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: N-(4-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(4-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide(1400651-19-5)
• EPA Substance Registry System: N-(4-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide(1400651-19-5)

Safety Data

• Hazardous Substances Data: 1400651-19-5(Hazardous Substances Data)

Upstream product

• 17680-55-6 7-bromo-1,2,3,4-tetrahydroisoquinoline 
• 181514-35-2 1-(7-bromo-3,4-dihydroisoquinolin-2(1H)-yl)-2,2,2-trifluoroethan-1-one 
• 1400653-03-3 7-bromo-2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonyl chloride 
• 1400653-04-4 7-bromo-N-(4-fluorophenyl)-2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide 
• 1400651-18-4 N-(4-fluorophenyl)-2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide 
• 91-21-4 1,2,3,4-tetrahydroisoquinoline 
• 55649-51-9 2-(trifluoroacetyl)-1,2,3,4-tetrahydroisoquinoline 

Relevant articles and documents

Identification of 2-[2-(4-tert-Butylphenyl)ethyl]-N-[4-(3-cyclopentylpropyl)- 2-fluorophenyl]-1,2,3,4-tetrahydroisoquinoline-6-sulfonamide as an Orally Active MGAT2 Inhibitor

We previously reported 2-[2-(4-tert-butylphenyl)ethyl]-N-(4-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline- 6-sulfonamide 2 as on orally available monoacylglycerol acyltransferase 2 (MGAT2) inhibitor which exhibited an in vivo efficacy at an oral dose of 100 mg/kg in a mouse oral lipid tolerance test. Further optimization of compound 2 to improve the intrinsic potency culminated in the identification of compound 11. Compound 11 showed a >50-fold lower IC50 against human MGAT2 enzyme than 2. Oral administration of 11 at a dose of 3 mg/kg in the oral lipid tolerance test resulted in significant suppression of triglyceride synthesis.

NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND

There are provided compounds represented by the following general formula (I) or pharmaceutically acceptable salts of thereof, which have a superior monoacylglycerol acyltransferase 2 inhibitory action: wherein Ring A represents a partially saturated heteroaryl group, an aryl group or a heteroaryl group, RB represents a C4-18 alkyl group, a C3-8 cycloalkyl group, a partially saturated aryl group, an aryl group, or the following formula (II): wherein V represents the formula -CR11R12-, -CO-, -CO-O-, or -CO-NH-, W represents a single bond or a C1-3 alkylene group, and Ring B represents a C3-8 cycloalkyl group, a C3-8 cycloalkenyl group, a partially saturated heteroaryl group, a saturated heterocyclyl group, an aryl group, or a heteroaryl group, Y represents a nitrogen atom or the formula N+(RF), RF represents a C1-4 alkyl group, and m and n, which may be the same or different, each represent an integer of 0 or 1.